Western Europe Regional Scope

 

Western Europe has some of the world’s most established paediatric oncology systems, supported by specialist childhood cancer centres, national cancer registries, multidisciplinary clinical teams and longstanding participation in international Wilms tumor research. Although healthcare delivery is organised independently within each country, centres across the region frequently follow SIOP-RTSG treatment principles and collaborate through European research groups, clinical trials and specialist networks such as ERN PaedCan.

​

For the purposes of this website, Western Europe follows the geographical classification used by the United Nations Statistics Division. This consistent regional definition allows Wilms tumor incidence, survival, treatment access and healthcare-system information to be organised clearly while supporting dedicated country pages and language-specific educational resources.

​

For the purposes of this website, Western Europe follows the geographical classification used by the United Nations Statistics Division.

​

Western Europe includes:

​

• Austria

• Belgium

• France

• Germany

• Liechtenstein

• Luxembourg

• Monaco

• The Netherlands

• Switzerland

 

France and Germany are the first countries included within the WCF Western Europe information cluster. Educational pages for other Western European countries may be added as suitable country-language literature and verified healthcare information become available.

​

The United Kingdom, Ireland and the Nordic countries are included within the WCF’s separate Northern Europe cluster.

​

Wilms Tumor Statistics in Western Europe

​

Incidence of Wilms Tumor

​

Wilms tumor is rare, and no single current registry publication provides a directly comparable annual total covering every Western European country. Regional estimates therefore need to be interpreted using population-based childhood cancer registry studies alongside national data.

​

A major European registry study reported an age-standardised incidence rate of 8.8 malignant renal tumours per million children under 15 each year during 1988–1997. Wilms tumor represented approximately 93% of those renal tumours, equivalent to an estimated Wilms tumor incidence of around 8.2 cases per million children annually.

​

The same study reported that approximately:

​

• 93% of recorded childhood renal tumours were Wilms tumors.

• 7% of Wilms tumors were bilateral, affecting both kidneys.

• Incidence increased by approximately 0.7% per year over the 20-year study period, although changes in registration and diagnosis may have contributed to this trend.

• Children aged approximately one to four years represented the largest diagnostic age group.

 

These figures are historical and should not be presented as a current regional surveillance report. However, they remain valuable because they are based on more than 5,000 childhood renal tumour registrations across Europe.

​

Source: Malignant renal tumours incidence and survival in European children — ACCIS study

​

Estimated Annual Wilms Tumor Cases in Western Europe

​

Using the published European incidence range together with the approximate number of children living in the nine Western European countries, WCF estimates that approximately 250–300 children under 15 may be diagnosed with Wilms tumor across Western Europe each year.

​

This is a WCF planning estimate, not an official regional case count. It should be used to communicate the likely scale of Wilms tumor across the region rather than as a substitute for country-level cancer registry statistics.

​

The actual number diagnosed in any year may vary because of:

​

• Annual population changes

• Differences in national age structures

• Natural variation associated with a rare cancer

• Registry completeness and reporting delay

• Differences between renal tumour and Wilms tumor classifications

• Inclusion or exclusion of adolescents in national datasets

• Diagnostic and pathological reclassification

 

France and Germany, because of their comparatively large childhood populations, are expected to account for a substantial proportion of Western Europe’s annual Wilms tumor diagnoses.

​

Bilateral and Predisposition-Associated Wilms Tumor

​

European registry evidence has historically indicated that approximately 7% of children with Wilms tumor have bilateral disease. Some children develop tumours in both kidneys at the same time, while others develop a tumour in the second kidney later.

​

Bilateral disease and certain inherited or constitutional conditions can affect treatment planning. Relevant conditions include:

​

• WAGR syndrome

• Denys–Drash syndrome

• Beckwith–Wiedemann spectrum

• Isolated hemihyperplasia or lateralised overgrowth

• Constitutional changes affecting WT1

• Constitutional 11p15 abnormalities

 

Children with bilateral, multifocal or unusually early-onset Wilms tumor may be referred for clinical genetics assessment. Treatment is generally planned with particular attention to preserving functioning kidney tissue wherever this can be achieved safely.

​

Wilms Tumor Survival in Western Europe

​

Regional Survival

​

Western Europe has experienced substantial improvements in Wilms tumor survival because of coordinated treatment protocols, centralised paediatric oncology, specialist surgery, pathology review, multidisciplinary decision-making and long-term clinical research.

​

Historical European data showed that five-year survival for Wilms tumor increased from approximately:

​

• 73% for children diagnosed in 1978–1982

• to 87% for children diagnosed in 1993–1997

 

The improvement was statistically significant in Western Europe as well as in several other European regions.

​

More recent studies from France and Germany show survival exceeding 90% for many groups of children, particularly those with localised disease and favourable-risk histology.

​

A population-based comparison of children treated in France, Germany and the United Kingdom reported adjusted overall survival for localised Wilms tumor of approximately:

​

• 97.9% in France

• 96.0% in Germany

 

For children with metastatic Wilms tumor, reported five-year overall survival was approximately:

​

• 84.7% in France

• 85.5% in Germany

 

These results demonstrate that metastatic Wilms tumor remains treatable for many children, but outcomes are less favourable than for disease confined to the kidney.

​

Further information: International comparison of Wilms tumor diagnosis and survival

​

Interpreting Survival Statistics

​

Regional survival percentages describe groups of children treated in particular periods. They cannot predict the outcome of an individual child.

​

A child’s prognosis may be influenced by:

​

• Whether the tumour is localised or metastatic

• Whether one or both kidneys are affected

• Histological risk group

• Tumour response to preoperative chemotherapy

• Blastemal tumour volume after chemotherapy

• Tumour rupture or surgical spill

• Lymph-node involvement

• Completeness of tumour removal

• Chromosomal or molecular tumour features

• Response of lung metastases to treatment

• Relapse and the site of relapse

• The child’s overall health and treatment tolerance

 

Families should ask their child’s paediatric oncology team to interpret survival evidence in relation to the individual diagnosis.

​

Wilms Tumor Mortality in Western Europe

​

Wilms tumor mortality is substantially lower in Western Europe than in regions where children face restricted access to diagnosis, surgery, radiotherapy, chemotherapy or supportive care. Nevertheless, deaths still occur, particularly among children with aggressive histology, persistent metastatic disease, treatment-resistant tumours or relapse.

​

No single harmonised database provides a current annual Wilms tumor death count for the entire Western European region. If approximately 250–300 children are diagnosed annually and long-term survival is broadly above 90%, a cautious population-level inference would suggest that approximately 15–30 children from each annual diagnostic cohort may ultimately die from Wilms tumor or treatment-related causes.

​

This is a derived WCF estimate, not a reported annual mortality statistic. Deaths may occur several years after diagnosis, which means it should not be interpreted as the number of Wilms tumor deaths recorded in a particular calendar year.

​

Continued mortality reduction depends on:

​

• Rapid access to specialist paediatric oncology

• Accurate staging and pathology

• Consistent protocol-based treatment

• Appropriate surgical expertise

• Access to radiotherapy when indicated

• Recognition and treatment of relapse

• Prevention and management of treatment complications

• Molecularly informed risk classification

• International research into high-risk disease

 

Wilms Tumor Stage in Western Europe

​

Regional Stage Data

​

There is currently no regularly updated public dataset presenting one standardised Wilms tumor stage distribution for all nine Western European countries. National registries and clinical study groups may record stage differently, and publicly reported figures often cover different diagnostic periods.

​

Across European SIOP-based treatment systems, Wilms tumor is generally assigned a postoperative stage after preoperative chemotherapy and surgery.

 

The principal SIOP stages are:

​

• Stage I: The tumour is limited to the kidney and has been completely removed.

• Stage II: The tumour has extended beyond the kidney but has been completely removed.

• Stage III: Residual non-haematogenous disease remains in the abdomen, or specified local risk factors are present.

• Stage IV: The tumour has spread through the bloodstream to distant organs, most commonly the lungs.

• Stage V: Both kidneys contain tumours at diagnosis.

 

Stages I–III describe different forms of local or regional disease. Stage IV indicates distant metastasis, while Stage V is determined by bilateral kidney involvement rather than by the extent of metastatic spread.

​

Because Western European centres commonly follow SIOP principles, the stage may be confirmed after the child has received preoperative chemotherapy and undergone nephrectomy or nephron-sparing surgery.

​

Stage and Outcome

​

Children with localised Wilms tumor generally have the most favourable outcomes. The France–Germany comparison demonstrates that overall survival for localised disease can approach or exceed 96% within experienced, protocol-led healthcare systems.

​

Metastatic disease is associated with a higher risk of recurrence and mortality, but five-year survival of approximately 85% has been reported in both France and Germany.

​

Stage alone does not determine risk. Two children with the same stage may receive different treatment because of differences in histology, tumour response, surgical findings, tumour volume, lymph-node status or molecular characteristics.

​

Histology and Risk Classification

​

Western European Wilms tumor treatment commonly uses the SIOP histological classification, which evaluates tumour tissue after preoperative chemotherapy.

​

Tumours are assigned to low-, intermediate- or high-risk histological groups. Histological findings may include:

​

• Completely necrotic Wilms tumor

• Epithelial-type Wilms tumor

• Stromal-type Wilms tumor

• Mixed-type Wilms tumor

• Regressive-type Wilms tumor

• Blastemal-type Wilms tumor

• Diffuse anaplastic Wilms tumor

 

Blastemal-type Wilms tumor following preoperative chemotherapy is considered high risk because the remaining blastemal component has demonstrated relative resistance to initial treatment. Diffuse anaplasia is also associated with a less favourable response and a higher risk of relapse.

​

The SIOP-RTSG UMBRELLA protocol aims to improve international consistency in:

​

• Tumour sampling

• Histological classification

• Pathology review

• Molecular analysis

• Assessment of blastemal tumour volume

• Biological sample collection

• Risk-adapted treatment research

 

How Wilms Tumor Is Treated in Western Europe

​

The SIOP Treatment Approach

​

Many Western European paediatric oncology centres follow protocols developed through SIOP-RTSG or closely related national study-group recommendations.

​

For children with a typical unilateral renal tumour, the European approach commonly includes:

​

1. Specialist imaging and multidisciplinary assessment

2. Preoperative chemotherapy

3. Surgery to remove the tumour

4. Central or expert pathology review

5. Postoperative treatment adapted to stage and histological risk

6. Radiotherapy for selected higher-risk situations

7. Structured surveillance after treatment

 

Under established SIOP protocols, children with localised disease have commonly received approximately four weeks of preoperative chemotherapy, while children with metastatic disease may receive approximately six weeks before surgery. The precise regimen depends on the active protocol and individual clinical circumstances.

​

Preoperative chemotherapy can reduce tumour size, facilitate surgical removal and lower the risk of tumour rupture. It also allows the tumour’s response to chemotherapy to contribute to postoperative risk classification.

​

Not every renal mass is treated identically. Infants, adolescents, children with bilateral tumours, children with an atypical renal mass and those with possible non-Wilms renal tumours may require a different diagnostic or surgical pathway.

​

Surgery and Specialist Centres

​

Wilms tumor surgery in Western Europe is usually undertaken in specialist paediatric surgical or paediatric oncology centres.

​

For unilateral disease, surgery commonly involves removal of the affected kidney and tumour. Kidney-preserving surgery may be considered in selected circumstances, particularly for:

​

• Bilateral Wilms tumor

• A child with only one functioning kidney

• Predisposition to future renal tumours

• Multifocal disease

• Significant underlying kidney impairment

• Carefully selected small unilateral tumours in expert centres

 

Surgical quality is important because tumour rupture, incomplete removal, inadequate lymph-node sampling and residual disease can influence staging and the need for additional treatment.

​

Radiotherapy

​

Radiotherapy is not required for every child with Wilms tumor. It is generally reserved for defined higher-risk circumstances, which may include:

​

• Certain Stage III tumours

• Unfavourable or high-risk histology

• Selected metastatic disease

• Persistent lung metastases

• Tumour rupture

• Incomplete surgical removal

• Some cases of relapsed Wilms tumor

 

Western European treatment groups continue to investigate how radiotherapy can be restricted to children most likely to benefit while reducing unnecessary exposure for lower-risk patients.

​

Childhood Cancer Care Systems in Western Europe

​

Western European countries generally provide paediatric cancer care through publicly funded or compulsory-insurance-based health systems. Children with suspected Wilms tumor are usually referred to specialist centres with access to paediatric oncology, surgery, pathology, radiology, radiotherapy, genetics, nephrology and intensive supportive care.

​

The precise organisation differs by country.

​

France

​

Childhood cancer services in France are coordinated through specialist paediatric oncology centres, national cancer policy and cooperative clinical groups. The Institut National du Cancer — INCa supports national cancer planning, standards, research and the organisation of specialist services.

The Société Française de lutte contre les Cancers et leucémies de l’Enfant et de l’adolescent — SFCE brings together professionals involved in childhood and adolescent cancer care and research.

​

French children with Wilms tumor may be treated through specialist centres participating in national and international renal tumour studies.

 

Germany

​

Germany has a highly structured paediatric oncology research and treatment system. The Gesellschaft für Pädiatrische Onkologie und Hämatologie — GPOH supports national clinical study groups and standardised treatment recommendations.

​

Childhood cancer registration is supported by the German Childhood Cancer Registry, which has contributed substantially to population-based research and long-term follow-up.

​

German paediatric oncology centres have played a major role in SIOP renal tumour trials, pathology research and the development of risk-adapted Wilms tumor treatment.

​

The Netherlands

​

Paediatric cancer care in the Netherlands is highly centralised through the Princess Máxima Center for Pediatric Oncology. This model concentrates treatment, research, pathology and multidisciplinary expertise within one national childhood cancer centre while working with shared-care hospitals.

Dutch clinicians and researchers have been prominent contributors to SIOP-RTSG, Wilms tumor pathology, molecular classification, survivorship and international trial coordination.

​

Belgium

​

Children with cancer in Belgium are treated in recognised paediatric oncology centres. The Belgian Society of Paediatric Haematology Oncology — BSPHO supports collaboration between specialist centres, clinical research and professional practice.

​

Belgian centres participate in European childhood cancer networks and international treatment protocols.

​

Switzerland

​

Switzerland provides paediatric oncology care through university and specialist children’s hospitals. The Swiss Paediatric Oncology Group — SPOG coordinates multicentre clinical research and participation in international childhood cancer studies.

​

Austria

​

Austria’s paediatric oncology services are concentrated in specialist centres. The St. Anna Children’s Hospital and Children’s Cancer Research Institute in Vienna are prominent centres for childhood cancer treatment and research. St. Anna also coordinates the European Reference Network for Paediatric Oncology.

​

Luxembourg, Liechtenstein and Monaco

​

Small countries may provide initial assessment and elements of supportive care nationally while using formal referral arrangements with larger specialist centres in neighbouring countries for highly specialised diagnosis or treatment.

​

The care pathway depends on national agreements, health-insurance authorisation, clinical need and the availability of paediatric oncology expertise.

​

European and Regional Governing Systems

​

Wilms tumor care in Western Europe is not governed by one regional health authority. It is supported through several connected layers:

​

• National ministries of health and healthcare regulators

• National childhood cancer plans

• Paediatric oncology professional societies

• National cancer registries

• Specialist treatment centres

• SIOP-RTSG clinical studies and treatment recommendations

• SIOP Europe

• ERN PaedCan

• European Union research and health programmes

• National and international ethics and medicines regulators

 

This structure enables countries to maintain responsibility for healthcare delivery while sharing specialist knowledge, research protocols and expert review across borders.

​

SIOP-RTSG & Wilms Tumor Research

​

The International Society of Paediatric Oncology Renal Tumour Study Group is one of the most important research collaborations affecting Wilms tumor care in Western Europe.

​

SIOP renal tumour studies have helped establish:

​

• Preoperative chemotherapy as a standard European approach

• Postoperative stage classification

• Treatment based on histological risk

• Reduced treatment for selected lower-risk patients

• More intensive treatment for higher-risk groups

• Central pathology review

• Standardised tumour sampling

• International data collection

• Long-term monitoring of outcomes and late effects

 

The UMBRELLA SIOP-RTSG 2016 protocol was developed to harmonise the diagnosis, pathology and molecular investigation of childhood renal tumours internationally.

​

Its research objectives include identifying children who may benefit from reduced treatment and those who require new or more intensive therapeutic strategies.

​

ERN PaedCan and Cross-Border Expertise

​

The European Reference Network for Paediatric Cancer — ERN PaedCan connects specialist childhood cancer hospitals across Europe.

​

The network reports:

​

• 79 full-member hospitals in 21 countries

• 11 affiliated hospitals in seven countries

• Coverage extending across the European Union and Norway

 

ERN PaedCan supports:

​

• Virtual multidisciplinary tumour boards

• Cross-border professional consultation

• Specialist clinical recommendations

• Exchange of diagnostic and treatment expertise

• Education and professional training

• European clinical-practice guidance

• Collaboration with SIOP Europe and national groups

 

Its Clinical Patient Management System enables healthcare professionals to seek virtual input from specialists in other countries. The aim is for expertise to travel across borders even when the patient does not.

​

Participation in ERN PaedCan does not mean every child requires cross-border treatment. Most children are treated within their national healthcare system. Cross-border consultation may be considered when a diagnosis or treatment decision is particularly rare or complex.

​

Clinical Research Priorities in Western Europe

​

Because survival for standard-risk Wilms tumor is already high, Western European research increasingly focuses on maintaining cure rates while reducing treatment-related harm.

​

Major priorities include:

​

• Improving outcomes for high-risk histology

• Identifying molecular predictors of relapse

• Reducing chemotherapy for very-low-risk disease

• Limiting anthracycline exposure

• Reducing radiotherapy where safely possible

• Improving treatment for relapse

• Preserving kidney function in bilateral disease

• Increasing the use of nephron-sparing surgery

• Standardising pathology and molecular testing

• Understanding inherited predisposition

• Monitoring long-term cardiovascular and renal health

• Measuring educational, psychological and social outcomes

• Improving transition from paediatric to adult survivorship care

 

International collaboration is essential because Wilms tumor is rare. Individual countries may not diagnose enough children in a particular risk group to answer research questions quickly without pooling data.

​

Cancer Registries & Regional Data Quality

​

Western Europe contains several established national and regional childhood cancer registries. These registries help researchers monitor:

​

• Incidence

• Age at diagnosis

• Survival

• Mortality

• Geographic variation

• Second cancers

• Long-term outcomes

• Changes in treatment results over time

 

However, direct country comparisons require caution. Differences can arise from:

​

• Registry coverage

• Diagnostic periods

• Follow-up duration

• Age limits

• Tumour classification

• Inclusion of non-Wilms renal tumours

• Stage definitions

• Statistical methods

• Treatment protocols

 

For this reason, older harmonised European studies may sometimes provide more reliable regional comparisons than combining unrelated current figures from individual national sources.

​

Improved harmonisation of national registry, clinical-trial, pathology and molecular data is an important regional priority.

​

Survivorship & Long-Term Follow-Up

​

Most children treated for Wilms tumor in Western Europe become long-term survivors. As survival has improved, greater attention has been given to health problems that can appear years after treatment.

​

Follow-up may consider:

​

• Function of the remaining kidney

• Blood pressure

• Urine protein

• Kidney filtration

• Heart health after anthracycline chemotherapy

• Growth and development

• Fertility and reproductive health

• Musculoskeletal effects of radiotherapy

• Lung health

• Second cancer risk

• Emotional wellbeing

• Education and employment

• Transition to adult healthcare

 

Follow-up plans vary according to treatment exposure. A child treated with surgery and limited chemotherapy may require different surveillance from a child who received anthracyclines, abdominal radiotherapy, lung radiotherapy or treatment for relapse.

​

Families should receive an individual treatment summary and long-term follow-up plan where these are available.

​

Regional Strengths & Continuing Priorities

​

Regional Strengths

​

Western Europe benefits from:

​

• Established specialist paediatric oncology centres

• National or near-national childhood cancer registration

• Multidisciplinary treatment teams

• Access to paediatric surgery and radiotherapy

• Long-standing participation in international studies

• Central pathology and imaging review

• Strong clinical and laboratory research capacity

• Cross-border European expert networks

• Increasing attention to survivorship

• Publicly funded or insurance-supported treatment systems

 

Continuing Priorities

​

Important priorities remain despite high overall survival:

​

• Reducing diagnostic delay

• Ensuring consistent access to specialist centres

• Improving outcomes for metastatic and high-risk disease

• Developing more effective relapse treatment

• Minimising treatment-related heart and kidney damage

• Preserving renal tissue in bilateral disease

• Expanding access to molecular testing

• Harmonising long-term follow-up

• Improving psychosocial and educational support

• Publishing more current country-comparable statistics

• Ensuring families receive understandable information in their own language

 

Small countries and families living far from specialist centres may face additional travel, coordination and cross-border care requirements.

​​​

WCF, WHO and the Global Initiative for Childhood Cancer

​

The Wilms Cancer Foundation’s educational work supports the principles of the World Health Organization’s Global Initiative for Childhood Cancer.

The GICC aims to achieve at least 60% survival for children with cancer globally by 2030, while reducing suffering and improving quality of life. Although survival for Wilms tumor is already substantially higher than this target in much of Western Europe, the region’s experience provides important evidence for international improvement.

​

Key lessons include:

​

• Treatment through specialist paediatric oncology services

• National and international clinical collaboration

• Standardised protocols

• Reliable access to essential medicines

• Specialist surgery and pathology

• Accurate cancer registration

• Risk-adapted treatment

• Long-term follow-up

• Family-centred educational resources

 

WCF educational literature linked from country pages may be developed in alignment with the WHO Global Initiative for Childhood Cancer and WCF initiative. This does not imply a formal WCF partnership with a national hospital, charity, professional society or government unless a partnership is expressly identified.

 

WCF’s Global Wilms Tumor Initiative

​

The Global Wilms Tumor Initiative — GWTI is the WCF’s framework for strengthening accessible, accurate and country-relevant Wilms tumor information internationally.

​

Within Western Europe, GWTI content aims to:

​

• Provide evidence-based regional information

• Develop country-specific Wilms tumor resources

• Make educational literature available in relevant languages

• Explain national treatment and referral systems

• Connect families with verified healthcare information

• Support awareness of symptoms and specialist referral

• Promote understanding of treatment and survivorship

• Highlight regional research and data gaps

• Support the wider goals of the WHO GICC

 

Country pages may include educational literature without suggesting that the WCF is formally partnered with a specific national organisation. Any current institutional partnership will be described clearly and separately.

​

Explore Wilms Tumor by Country

​

France

​

Explore Wilms tumor incidence, treatment, specialist paediatric oncology services, survival and French-language educational resources.

Read more about Wilms tumor in France.

​

Germany

​

Learn about Wilms tumor diagnosis, SIOP-based treatment, childhood cancer registration, clinical research and German-language family resources.

Read more about Wilms tumor in Germany.

​

Additional Western European country pages will be added as verified national information and suitable language resources become available.

 

References and Further Reading

​

• World Health Organization - Global Initiative for Childhood Cancer

​

• WHO - Childhood cancer overview

​

• Pastore et al. - Malignant renal tumours incidence and survival in European children

​

• SIOP-RTSG - UMBRELLA pathology and molecular biology protocol

​

• Nature Reviews Urology - UMBRELLA SIOP-RTSG 2016 protocol

​

• ERN PaedCan - European Reference Network for Paediatric Cancer

​

• ERN PaedCan - Network members, structure and governance

​

• European Commission - European Reference Networks

​

• UCL - Comparison of Wilms tumor diagnosis and survival in France, Germany and the UK

​

• National Cancer Institute - Wilms Tumor and Other Childhood Kidney Tumors Treatment

​

• United Nations Statistics Division - Standard Country and Area Codes

 

Medical, Statistical and Partnership Disclaimer

​

This page provides general educational information and is not a substitute for diagnosis, treatment or advice from a qualified paediatric oncology team. Families should discuss all medical decisions with the clinicians responsible for their child’s care.

​

Regional statistics describe populations rather than individual outcomes. Figures may originate from different diagnostic periods, age groups, registry systems and treatment protocols. Historical figures are identified where applicable. WCF-modeled estimates are planning calculations based on published incidence rates and regional childhood populations; they are not official registry totals or predictions of future cases.

​

Reference to WHO, the Global Initiative for Childhood Cancer, SIOP-RTSG, ERN PaedCan, national healthcare bodies or professional groups does not by itself indicate endorsement, funding or a formal partnership. Any confirmed WCF partnership will be stated explicitly.